Compare · CBLL vs MDT
CBLL vs MDT
Side-by-side comparison of CeriBell Inc. (CBLL) and Medtronic plc. (MDT): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CBLL and MDT operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
- MDT is the larger of the two at $116.66B, about 126.9x CBLL ($919.2M).
- CBLL has been more active in the news (17 items in the past 4 weeks vs 14 for MDT).
- MDT has more recent analyst coverage (25 ratings vs 8 for CBLL).
- Company
- CeriBell Inc.
- Medtronic plc.
- Price
- -
- -
- Market cap
- $919.2M
- $116.66B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NASDAQ
- NYSE
- IPO
- 2024
- News (4w)
- 17
- 14
- Recent ratings
- 8
- 25
Medtronic plc.
Medtronic plc develops, manufactures, distributes, and sells device-based medical therapies to hospitals, physicians, clinicians, and patients worldwide. It operates through four segments: Cardiovascular Portfolio, Neuroscience Portfolio, Medical Surgical Portfolio, and Diabetes Operating Unit. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; AF ablation products; insertable cardiac monitor systems; mechanical circulatory support; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves; percutaneous coronary intervention stents, surgical valve replacement and repair products, endovascular stent grafts, percutaneous angioplasty balloons, and products to treat superficial venous diseases in the lower extremities. The Medical Surgical Portfolio segment offers surgical products, including surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, surgical artificial intelligence and robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology and lung products, and various therapies to treat diseases. The Neuroscience Portfolio segment offers products for spinal surgeons; neurosurgeons; neurologists; pain management specialists; anesthesiologists; orthopedic surgeons; urologists; urogynecologists; interventional radiologists; ear, nose, and throat specialists; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems and robotic guidance systems used in robot assisted spine procedures; and therapies for vasculature in and around the brain. The Diabetes Operating Unit segment offers insulin pumps and consumables, and continuous glucose monitoring systems. The company was founded in 1949 and is headquartered in Dublin, Ireland.
Latest CBLL
- Chief Revenue Officer Manni Joseph S. sold $32,691 worth of shares (1,361 units at $24.02), decreasing direct ownership by 2% to 55,956 units (SEC Form 4) (tax liability)
- Senior VP, Finance and PAO Foehr David sold $44,425 worth of shares (1,852 units at $23.99) as part of a pre-agreed trading plan, decreasing direct ownership by 5% to 35,899 units (SEC Form 4) to cover withholding tax
- Chief Technology Officer Woo Raymond sold $47,536 worth of shares (1,979 units at $24.02), decreasing direct ownership by 1% to 194,729 units (SEC Form 4) (for tax liability)
- Chief Financial Officer Blumberg Scott sold $36,534 worth of shares (1,521 units at $24.02), decreasing direct ownership by 1% to 146,600 units (SEC Form 4) (tax liability)
- President and CEO Chao Xingjuan sold $145,753 worth of shares (6,068 units at $24.02), decreasing direct ownership by 0.77% to 781,731 units (SEC Form 4) to satisfy withholding tax
- Chief Financial Officer Blumberg Scott exercised 34,502 shares at a strike of $8.47 and sold $863,555 worth of shares (34,502 units at $25.03) as part of a pre-agreed trading plan (SEC Form 4)
- Amendment: SEC Form 4 filed by Chief Financial Officer Blumberg Scott
- President and CEO Chao Xingjuan sold $841,292 worth of shares (33,614 units at $25.03) as part of a pre-agreed trading plan, decreasing direct ownership by 4% to 787,799 units (SEC Form 4)
- President and CEO Chao Xingjuan exercised 33,096 shares at a strike of $3.31, increasing direct ownership by 4% to 821,413 units (SEC Form 4)
- Director Taylor Joseph Michael sold $306,423 worth of shares (13,095 units at $23.40), decreasing direct ownership by 21% to 48,478 units (SEC Form 4)
Latest MDT
- EVP, Pres MedSurg and Americas Marinaro Michael covered exercise/tax liability with 1,084 units of Ordinary Shares, decreasing direct ownership by 0.92% to 116,336 units (SEC Form 4)
- Medtronic announces cash dividend for second quarter of fiscal year 2027
- SEC Form DEFA14A filed by Medtronic plc.
- SEC Form DEF 14A filed by Medtronic plc.
- Orchestra BioMed Reports Second Quarter 2026 Financial Results and Highlights Recent Business Updates
- Medtronic announces expanded CE Mark indication for Affera™ Mapping and Ablation System and Sphere-9™ Catheter for treatment of ventricular arrhythmias
- Chief Accounting Officer Blomquist Denise L. covered exercise/tax liability with 212 units of Ordinary Shares and was granted 2,337 units of Ordinary Shares, increasing direct ownership by 14% to 16,998 units (SEC Form 4)
- EVP & President, Neuroscience Thompson Kweli covered exercise/tax liability with 1,739 units of Ordinary Shares and was granted 6,923 units of Ordinary Shares, increasing direct ownership by 17% to 35,390 units (SEC Form 4)
- SVP, Chief HR Officer Walter Matthew R. covered exercise/tax liability with 1,675 units of Ordinary Shares and was granted 5,769 units of Ordinary Shares, increasing direct ownership by 11% to 39,928 units (SEC Form 4)
- EVP, GC and Secretary Quinn Michelle was granted 6,346 units of Ordinary Shares, increasing direct ownership by 31% to 26,721 units (SEC Form 4)